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Hashimoto’s encephalopathy (HE) is a well-established disease that occurs most commonly in patients with
euthyroidism. We report 3 patients diagnosed with HE. Cases 1 and 2 were young females who had experienced
intractable seizures and presented with cognitive impairment. Reversible slow waves on the electroencephalogram
(EEG), and nearly complete recovery of cognition, were noted after steroid treatment. Case 3 was an elderly male
who presented with a sudden onset of vertigo, diplopia, and recurrent gait ataxia. Reversible hypoperfusion in the
upper portion of the left cerebellum, on 99mTc hexamethylpropyleneamine oxime (HMPAO) single photon emission
computed tomography (SPECT), was noted after steroid treatment. We also review 25 cases from the literature
of patients diagnosed with HE. All patients had antithyroid antibodies. A reversible inflammatory process is supported
by brain magnetic resonance imaging, SPECT, EEG and cerebrospinal fluid studies. Vasculitis is the most probable
pathogenesis according to laboratory findings. Steroids are the treatment of choice, and result in a favorable outcome
when administered early in the disease course. [J Chin Med Assoc 2005;68(2):77–81]
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Introduction
Hashimoto’s encephalopathy (HE) is a distinct clinical
entity appearing most often with euthyroidism or mild
subclinical hypothyroidism. Clinical features of HE
clearly differ from those of typical myxedematous
encephalopathy. Diagnosis of HE requires exclusion
of other causes of encephalopathy, such as infection,
metabolic, toxic, neoplastic, paraneoplastic, or vascular
causes. The clinical expression includes focal neurolo-
gic deficits, diffuse encephalopathy with hypertonia,
tremor, myoclonus, choreoathetosis, complex-partial
or generalized seizures, and frontotemporal neuro-
psychologic dysfunction. Reversible slowing on the
electroencephalogram (EEG), and hypoperfusion on
single photon emission computed tomography
(SPECT), have been reported in the literature.1,2 We
report 3 patients with HE, with reversible EEG or
SPECT abnormalities after treatment with steroids
or in combination with levothyroxine. We also review
25 cases of HE in the literature and compare their
characteristics with ours.1–14
Case 1
A 21-year-old female had some visual hallucinations at
age 17 years. These disappeared completely approxi-
mately 2 weeks later without treatment.
Two weeks before admission to our hospital, the
patient developed auditory hallucinations with impaired
cognition. Cerebrospinal fluid (CSF) study at another
hospital revealed a red blood cell count (RBC) of
181/mm3, white blood cell count (WBC) of 7/mm3
(neutrophil:lymphocyte ratio of 2:5), a protein level of
15 mg/dL, and a normal glucose level. Microbiologic
study was negative. Brain computed tomography (CT),
toxicology and thyroid function studies were also
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normal. Seizures developed during hospitalization
and the patient’s mental state continued to deteriorate.
Two days later, she became agitated, confused and,
finally, bedridden.
The patient was brought to our hospital, and
neurologic examination revealed drowsy conscious-
ness, generalized rigidity, increased deep-tendon and
flexor-plantar reflexes. CSF study revealed an RBC
of 315/mm3, a WBC of 2/mm3, a protein level of
37 mg/dL, and a normal glucose level. Microbiologic
study of CSF was normal. Phenytoin was prescribed
for recurrent generalized tonic-clonic seizures. An
EEG revealed poor alpha rhythms and frequent, diffuse,
random, polymorphic theta waves. 99mTc hexamethyl-
propyleneamine oxime (HMPAO) brain SPECT and
thyroid function were normal. Brain magnetic reson-
ance imaging (MRI) disclosed focal high-signal
intensity on T2-weighted imaging (T2WI) and fluid-
attenuated inversion recovery (FLAIR) images at the
right posteroinferior aspect of the cerebellar hemisphere
and vermis without significant contrast enhancement.
Acyclovir was prescribed for possible herpes encephali-
tis. Autoimmune studies, including serum antinuclear
antibodies (ANA) and anticardiolipid antibodies
(ACA), were normal. As central nervous system (CNS)
vasculitis was suspected, intravenous dexamethasone
5 mg every 8 hours was given on day 4.
Unfortunately, aspiration pneumonia developed
with respiratory failure and the patient was admitted
to the intensive care unit on day 6. A repeated CSF
study on day 8 revealed an RBC of 29/mm3, a WBC
of 1/mm3, a protein level of 15 mg/dL, and a normal
glucose level. An elevated CSF immunoglobulin-G
index (IGGI) of 0.62 was noted, but no oligoclonal
bands were present. Dexamethasone was prescribed
for only 12 days because pneumonia did not improve.
On the day of discharge, after nearly 3 months of
hospitalization, the patient could walk for about 300
meters. A follow-up EEG study 3 months later revealed
well-organized alpha activity, although the activity
decreased in the left temporal lobe. Follow-up MRI 5
months later revealed no residual high-signal lesions in
the right cerebellar hemisphere on T2WI. However,
the patient still became agitated intermittently, with
visual hallucinations and slurred speech. Tremors and
myoclonic jerks over all 4 limbs were also present.
Antithyroid autoantibodies were surveyed and revealed
an elevated level of antithyroid peroxidase (anti-TPO)
antibody (100 IU/mL; normal < 35 IU/mL). Anti-
thyroglobulin (anti-TG) antibody level was normal.
HE was diagnosed and oral prednisolone 60 mg/day
was prescribed. The patient’s cognition improved
and she became much less agitated. An EEG after 5
months of steroid treatment disclosed only residual
focal slow waves in the left temporo-occipital lobe.
The patient’s mental function recovered completely
without seizures or hallucinations after 9 months of
steroid therapy.
Case 2
A 25-year-old female, who was about to be married,
experienced progressive deterioration of consciousness
for 8 days. Before that, she had been happily preparing
for her wedding. On November 10, 2001, she began
talking to herself. During these episodes, she repeated
the same words over and over. She underwent examina-
tion at another hospital, but no definite diagnosis was
made. Her cognition gradually worsened and she was
brought to our hospital on November 19, 2001. She
appeared agitated and shouted continuously. She
presented generalized rigidity without focal weakness.
Normal deep-tendon and flexor-plantar reflexes were
present. Brain MRI was normal and CSF study revealed
an RBC of 12/mm3, WBC of 6/mm3, (neutrophil:
lymphocyte ratio of 4:2), glucose level of 71 mg/dL,
and a protein level of 42 mg/dL. An EEG suggested
a hypersomnolent state with symmetrical sleep spindles
and rare slow waves. Intravenous acyclovir 500 mg
every 8 hours was prescribed for 10 days, beginning on
November 21, 2001, due to suspicion of herpes en-
cephalitis. Two days later, further CSF study disclosed
an elevated IGGI of 0.7 and positive oligoclonal
bands. Other microbiologic studies of CSF, which
included tests for syphilis, fungus, cryptococcus,
tuberculosis, and polymerase chain reaction (PCR)
testing for both enterovirus and herpes virus, were all
negative. Serum ANA were present with a speckled
pattern and titer of 1:160. Levels of thyroid stimulation
hormone (TSH) and free thyroxine were normal, but
high levels of anti-TG antibodies (1,209 IU/mL) and
anti-TPO antibodies (448 IU/mL) were present.
Other autoimmune titers including anti-double-
strand-DNA antibodies, ACA, lupus-anticoagulant
(LA), anti-Sjögren’s syndrome A antibodies (SSA),
anti-Sjögren’s syndrome B antibodies (SSB), and anti-
neutrophil cytoplasmic antibodies (ANCA), were
negative. Intravenous hydrocortisone was prescribed.
Generalized tonic-clonic seizures developed on
November 26, 2001. On December 5, 2001, 5 days
after the completion of hydrocortisone therapy, the
patient became cooperative and no more seizures
developed. Aspiration pneumonia was treated success-
fully with intravenous penicillin. The patient could
communicate with others using simple phrases and, on
Hashimoto’s encephalopathy
79J Chin Med Assoc • February 2005 • Vol 68 • No 2
December 12, 2001, could walk for short distances
with little assistance. Follow-up brain MRI was nor-
mal. A follow-up EEG on December 17, 2001 revealed
diffuse slow waves, although cognition had improved.
Two weeks later, the patient’s cognition fully recovered.
Follow-up levels of anti-TG antibodies decreased to
757 IU/mL, and anti-TPO antibodies to 172 IU/mL.
The patient recovered and remained well through-
out the following year; the EEG returned to normal in
December 2002.
Case 3
A 68-year-old male experienced a sudden onset of
vertigo and unsteadiness on July 22, 2001. Neurologic
examination suggested intact mentality and conscious-
ness, but diplopia was noted with ataxic gait. Brain
MRI disclosed multiple high-signal spots in bilateral
subcortical white matter on T2WI. An inflammatory
process in the CNS was suspected. CSF study disclosed
a normal cell count, an elevated protein level of
83 mg/dL, and a normal glucose level. CSF IGGI was
normal, without oligoclonal bands. 99mTc HMPAO
SPECT revealed decreased uptake in the upper portion
of the left cerebellum. Because cerebellitis was sus-
pected, steroids were prescribed and gait ataxia grad-
ually improved. 99mTc HMPAO SPECT was performed
2 weeks later, after steroid treatment, and revealed
improved perfusion of the previously hypoperfused
area. The patient was discharged with a prescription
for oral prednisolone 30 mg/day and was followed-up
at an outpatient clinic.
Unfortunately, 2 months later, vertigo and gait
ataxia recurred after tapering of steroids. 99mTc HMPAO
SPECT revealed decreased perfusion in the left basal
ganglion and left temporal area. Steroids were pre-
scribed again and the patient’s symptoms improved.
Five months later, vertigo recurred and consciousness
deteriorated over 2 days. Visual hallucinations also
occurred. A brain CT scan revealed possible left basal
ganglion infarction and edematous change of the left
cerebellar hemisphere. An EEG disclosed generalized
asynchronous polymorphic theta and delta waves with
background slowing. CSF study revealed a normal cell
count, and normal protein and glucose levels. Other
laboratory data included TSH 50.8 +IU/mL (normal,
0.4–4.0 +IU/mL), and free thyroxine < 2 pg/mL
(normal, 7–19 pg/mL). The anti-TPO antibody level
was more than 1,000 IU/mL. Thyroid sonography
disclosed generalized heteroechogenicity compatible
with Hashimoto’s thyroiditis. Levothyroxine was
prescribed without steroids, and the patient gradually
regained consciousness. He was discharged 2 weeks
later. In the following 8 months, he remained stable,
with only mild ataxia and without cognitive impairment,
during levothyroxine therapy.
Discussion
Clinically, suspicion of HE arises from the presence of
cognitive impairment or focal neurologic deficit, the
presence of antithyroid autoantibodies, and the exclu-
sion of infective, metabolic, toxic, neoplastic, para-
neoplastic and vascular causes. Two types of HE have
been proposed by Kothbauer-Margreiter et al.7 The
first is vasculitic (type I) and is characterized by stroke-
like episodes with transient focal neurologic deficits
with or without cognitive impairment and confusion,
sometimes in combination with epileptic seizures.
Its course is relapsing-remitting with symptomless
intervals. The second is diffuse-progressive (type II)
and has an insidious onset and a progressively deteri-
orating course without focal neurologic signs. Brisk
tendon reflexes and pyramidal tract signs are frequently
found. Patients with the diffuse-progressive type may
become confused, psychotic, somnolent or comatose.
Seizure disorders are regularly present.
Cases 1 and 2, both young females, presented with
diffuse cognitive impairment, including hallucinations,
disorientation, delirium, and self-talk. Both patients
had hypertonicity and recurrent seizures, which were
resistant to anticonvulsants. Both had euthyroidism,
and the diagnosis of HE was made based on impaired
cognition, the presence of antithyroid autoantibodies,
and the response to steroid therapy. These 2 clinical
presentations were similar to the diffuse-progressive
type of HE. Both patients had complete remission and
reversible EEG abnormalities after steroid treatment.
In our review of the literature, EEG findings in HE
patients varied considerably. Diffuse slow waves, which
predominantly involved frontal-temporal areas, were
the most common finding and were present in 89.2%
of patients. The EEG in case 1 showed diffuse random
polymorphic theta waves, which initially recovered to
well-organized alpha activity before steroid treatment,
with only residual focal slow waves present in the left
temporo-occipital lobe after steroid treatment. Case 2
presented symmetrical sleep spindles and rare slow
waves. Improvement in cognition was noted earlier
than improvement in the EEG presentation. The EEG
returned to normal at 1-year follow-up. Case 3 was an
elderly male classified as having the vasculitic type of
HE. No seizures were noted. The diagnosis of HE was
made due to the presence of diplopia, ataxia, the
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presence of serum antithyroid autoantibodies, and the
response to steroid therapy. The patient had 3 epi-
sodes of attacks. He recovered cognition, although
mild ataxia persisted. In our literature review, 3 of 4
patients with SPECT studies had decreased cerebral
perfusion and 2 of them had reversible hypoper-
fusion. Forchetti et al reported an HE patient with
diffuse and homogeneous cerebral hypoperfusion on
SPECT, which normalized after steroid treatment.2
Our case 3 underwent a series of 99mTc HMPAO
SPECT studies, which also disclosed reversible hypo-
perfusion in the left cerebellar hemisphere after steroid
treatment.
Our literature review (Table 1) revealed a mean age
of 44 years with a wide age range (12–77 years), and
89.2% of cases were female. Both types of HE have
favorable prognosis if treatment is started early, al-
though type II patients appear to have a more favor-
able prognosis than type I patients. Fifteen patients
(53.5%) were type I and 13 patients (46.4%) were type
II; 7 type I patients (46.6%) and 9 type II patients
(69.2%) experienced complete remission. The poorer
outcome of type I patients might be due to attacks
recurrently involving the same cerebral structures.
Our case 3 had recurrent attacks of the left cerebellar
hemisphere that resulted in residual ataxia.
In 1995, a female patient was reported with HE in
Taiwan;5 the clinical picture and EEG slowing were
similar to those in our first 2 cases. The patient had
subclinical hypothyroidism related to Hashimoto’s
thyroiditis. However, CSF and brain imaging studies
were normal in this case, and thus different from ours.
In our review of the literature, HE most commonly
affected patients with euthyroidism (Table 1). Twenty
patients (71.5%) presented with euthyroidism, 8
(28.5%) had hypothyroidism. Levothyroxine supple-
mentation does not correlate well with prognosis.
That is to say, thyroid status does not correlate well
with HE severity. Twenty patients (71.5%) had an
elevated protein level, IGGI or oligoclonal bands in
CSF studies. Nine patients underwent cerebral angio-
graphy and all had normal findings. Twenty-two
Table 1. Summary of clinical findings in Hashimoto’s encephalopathy
Case Age (yr)/Gender Type I Type II Steroid use Thyroid status Levothyroxine use Outcome
13 57/F + + N – R
23 14/F + + N + CR
33 18/F + + N + R
43 58/F + + N + CR
53 56/F + + N + CR
64 12/F + + N – DC
75 15/F + + H + CR
81 68/F + + N + CR
91 28/F + + N – MCI
106 78/F + + N + MCI
116 73/F + + N + MCI
127 47/F + + N – CR
137 50/F + + H + CR
147 32/F + + N + CR
157 57/F + + N – MCI
167 28/F + – H + CR
177 40/F + – N + CR
188 67/M + + N – RMD
192 59/F + – N + RMD
209 77/F + + H ? Death
2110 47/M + + N – CR
2211 28/F + + N – CR
2312 17/F + + H + CR
2413 47/F + + H + RMD
2514 47/F + + H + CR
26 21/F + + N – CR
27 25/F + + N – CR
28 68/M + + H + RMD
CR = complete remission; DC = deteriorating cognition; F = female; H = hypothyroidism; M = male; MCI = mild cognitive impairment; N = euthyroidism;
R = relapsing attacks; RMD = residual movement dysfunction.
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patients underwent brain MRI studies. Ten patients
(45.4%) had high-signal lesions in T2WI or FLAIR;
7 of these patients (70%) had lesions in bilateral
subcortical white matter, and the other 3 had lesions
involving the cerebellum or brain stem. None of the
10 patients had post-contrast enhancement. Four
patients (18.1%) had only cerebral atrophy, which
most commonly involved the temporal lobe. Eight
patients (36.3%) had normal findings.
Several mechanisms have been postulated for HE,
including autoimmune cerebral vasculitis,9 estrogen,11
central effects of excessive thyrotropin-releasing hor-
mone, and an unidentified common antigen between
the brain and the thyroid gland.15 The most probable
pathogenesis of HE is vasculitis, which is supported by
two histopathologic studies.9,16 Shibata et al reported
a patient with an MRI finding of high-signal intensity
in the left parieto-occipital lobe on T2WI.16 This pa-
tient also showed angiitis and lymphocyte infiltration
of the entire wall of small parenchymal vessels, both
arterioles and venules, in a histopathologic examination.
In 2000, Nolte et al reported histopathologic data for
a patient, which disclosed prominent infiltration of
lymphocytes within leptomeningeal vessel walls.9
The role of antithyroid antibodies has often been
debated, since they are found in 10% of normal healthy
humans.3 The pathogenetic role of antithyroid
autoantibodies has not been established, because such
autoantibodies in CSF were detectable in only 1 pa-
tient.3 Nevertheless, such autoantibodies are now
regarded as indicators of HE.
HE is a well-established, distinct clinical entity that
responds to steroid treatment. If such treatment is
started early, a favorable outcome can be expected in
85.7% of cases, with complete remission or only mild
neurologic deficits, such as cognitive impairment,
myoclonus, tremors, ataxia and apraxia.
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